|Bid||288.00 x 800|
|Ask||306.99 x 1000|
|Day's Range||296.80 - 311.14|
|52 Week Range||215.78 - 374.99|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||9.56|
|Earnings Date||Apr 21, 2020 - Apr 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||335.17|
UnitedHealth Group Chief Scientific Officer Ken Ehlert joins Yahoo Finance’s Anjalee Khemlani and Seana Smith to discuss the new testing kit that will enable patients to test themselves for the virus at home.
Vertex is embarking on some of its riskiest work in several years, bringing on a new CEO while overhauling its product portfolio for what its longtime former leader dubbed “Vertex 3.0”.
Biogen is joining the hunt for a coronavirus treatment with Vir Biotechnology. Further, the company is still working on an Alzheimer's drug. So, is now the time to buy Biogen stock?
Biogen (BIIB) today announced that the first patient has been treated in the global clinical study, DEVOTE. The study is designed to evaluate the safety, tolerability and potential for even greater efficacy of SPINRAZA (nusinersen) when administered at a higher dose than currently approved for the treatment of spinal muscular atrophy (SMA).
Identifying a treatment for the novel coronavirus is perhaps the most vital scientific problem of the moment, particularly during the wait for a vaccine.
The U.S. Food & Drug Administration has authorised the start of a mid-stage trial by U.S.-Israeli NeuroRx and Relief Therapeutics for the use of Aviptadil to treat Acute Respiratory Distress in coronavirus patients. The FDA issued a "study may proceed" letter 24 hours after their investigational new drug application. NeuroRx is a privately held drug development company.
As the government prepares to bail out industries amid the Covid-19 pandemic, stock buybacks are falling out of favor. One sector that does a lot of repurchases? The biopharma industry.
Swiss drugmaker Novartis on Friday won a key European recommendation for its gene therapy Zolgensma against spinal muscular atrophy (SMA), clearing a hurdle for $2.1 million per patient treatment for approval in Europe within months. The European Medicines Agency's (EMA) Committee for Human Medicines (CHMP) recommended conditional approval for Zolgensma for certain patients: those with Type 1 SMA, the severest form of the disease, or for SMA patients with up to three copies of the so-called SMN2 gene, an indicator of the disease's severity.
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
The number of global cases of the coronavirus that causes COVID-19 edged closer to half a million on Thursday, and U.S. jobless claims soared to a historic level as workers were laid off or furloughed as non-essential services were ordered to close.
Vir Biotechnology Inc. teamed with WuXi Biologics and Biogen Inc. to rush a potential treatment for COVID-19 patients into clinical trials, possibly as soon as June. San Francisco-based Vir (NASDAQ: VIR) said early Wednesday that its potential antibody treatment for the coronavirus that causes COVID has been transferred "several weeks ago" to China-based WuXi and Biogen (NASDAQ: BIIB) and could be tested in humans within three to five months. Vir's candidate is the latest potential treatment or vaccine rushed into service to defeat COVID.
S&P; Dow Jones Indices ("S&P; DJI") announced today that preliminary Q4 2019 S&P; 500® stock buybacks, or share repurchases, were $181.6 billion – a 3.2% increase over Q3 2019's $175.9 billion, but down 18.6% from Q4 2018's $223.0 billion record.
Global events, meetings and symposiums are being canceled in droves as a precautionary measure to help contain the coronavirus pandemic. Biogen Inc (NASDAQ: BIIB) executives attended a conference sponsored by Cowen in Boston last month have become responsible for most cases of COVID-19 in Massachusetts, according to CNN. A Biogen executive from Italy who was reportedly infected with SARS-CoV-2 spread it to his unsuspecting colleagues.The following are medical meetings that have been canceled or postponed: Canceled Meetings (with original schedule and venue) * American Academy of Allergy, Asthma and Immunology: March 13-16 in Philadelphia, Pennsylvania * American Academy of Dermatology: March 20-24 in Denver, Colorado * Endocrine Society-ENDO 2020: March 27-31 in San Francisco, California * The Society of Gynecologic Oncology 2020 Annual Meeting on Women's Cancer: March 28-31 in Toronto, Ontario, Canada. * American Academy of Neurology: April 25-May 1 in Toronto, Canada * American College of Physicians' Internal Medicine Meeting: April 23-25 in Los Angeles, CaliforniaPostponed Meetings * European Society of Radiology 2020 meeting: shifted from March 11-15 to July 15-19; to be held in Vienna, Austria * European Breast Conference: shifted from March 18-20 to beyond September; to be held in Barcelona, Spain * 35th Annual Congress of the European Association of Urology: shifted from March 20-23 to July 17-21; to be held in Amsterdam, the Netherlands * 2020 Muscular Dystrophy Association Clinical & Scientific Conference: shifted from March 22-25 to a yet-to-be-announced date; to be held in Orlando, Florida * The European Association for the Study of Liver's International Liver Congress 2020: shifted from April 15-19 to beyond August; to be held in London, U.K. * The American Association for Cancer Research 2020 Annual Meeting: shifted from April 24-29 to later this year; to be held in San Diego, CaliforniaSome of the associations have taken advantage of technology and scheduled virtual meetings: * The annual Conference on Retroviruses and Opportunistic Infections scheduled between March 7-10 was canceled and instead virtual meetings were held between March 8-10. * The American College of Cardiology cancelled its Scientific Session and World Congress of Cardiology scheduled to take place in March 28-30 in Chicago, Illinois. ACC said it will announce a virtual schedule instead.Related Links:10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades8 Biotechs With Coronavirus Vaccines In Development See more from Benzinga * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection * The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
U.S. drugmaker Biogen Inc said on Wednesday that some patients on its drug Spinraza - which treats a rare disorder called spinal muscular atrophy (SMA) - are having their treatments postponed to prioritize COVID-19 patients. Biogen did not give further details about how many patients were having their treatment delayed by the fast-moving outbreak, where they are located or how long the delays are. Patients group Cure SMA said in a statement released earlier on Wednesday that receiving the drug on time is a high priority for SMA patients but that a "few weeks delay should not have a huge impact."
Health care, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The health care sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and health care providers. Some of the largest health care stocks in the world include Johnson & Johnson (JNJ) and Pfizer, Inc. (PFE).
Biogen Inc. (BIIB) today announced that the Biogen Foundation has committed $10 million to support global response efforts and communities around the world impacted by the COVID-19 pandemic. The funds will be used to address immediate critical needs, with the majority of donations going to support non-profit organizations in the U.S., including Massachusetts and North Carolina, in Italy and in other impacted countries worldwide. This adds to the donation made by Biogen China to the Red Cross Society of China.